University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Nola M. Hylton, PhD

Nola M. Hylton, PhD

Professor in Residence, Department of Radiology; and Leader, Breast Imaging Research Group, UCSF

Cancer Center Program Memberships

Breast Oncology

Research Summary

I am an imaging scientist and breast cancer researcher with broad experience in the area of biomedical research. Work in my laboratory focuses on the development of MRI techniques for breast cancer diagnosis and treatment response assessment. My laboratory works closely with a multi-disciplinary team of radiologists, surgeons, oncologists, basic science researchers and advocates to optimize MRI methods for the clinical management of breast cancer patients. The overall goal of our interdisciplinary research program is to develop imaging-based biomarkers that can be used in combination with clinical and molecular information to individualize treatment strategies.

I lead as Principal Investigator, the multi-center ACRIN trials 6657 and 6698, evaluating dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI respectively, for assessing treatment response as part of the ISPY-1 and ISPY-2 neoadjuvant breast cancer trials. Under an NCI Academic-Industrial Partnership (AIP) grant with commercial partner Hologic, Inc., (R01 CA132870), my laboratory developed and deployed a software platform for real-time measurement of breast tumor response using DCE-MRI, for use in clinical trials. The Hologic software received FDA IDE approval in 2010 and is now incorporated in the response-adaptive patient randomization engine of ISPY-2. Under prior funding from the NCI Quantitative Imaging Network (QIN) (U01 CA151235), my laboratory led efforts to improve the integration of quantitative imaging (QI) in breast cancer clinical trials through the development of standards and quality control processes and improved diffusion-weighted MRI approaches for tumor response measurement.

As an applied scientist involved in the early development of breast MRI, I believe I bring a unique perspective and appreciation of the factors that drive and shape the development of new breast imaging technologies. I have served on and chaired numerous grant review panels in both the areas of medical imaging and breast cancer research.

I am an active educator and faculty member at UCSF and in the UCSF/UC Berkeley Bioengineering Graduate Program and I teach formally in the UCSF Master’s in Biomedical Imaging degree program. I have been involved in the training and research supervision of graduate students, post-doctoral fellows and junior faculty for over 20 years.

Education

Massachusetts Institute of Technology (M.I.T.), B.S., 1979, Chemical Engineering
Stanford University, Ph.D., 1985, Applied Physics


Professional Experience

  • 1985 - 1992
    Assistant Professor in Residence, Department of Radiology, University of California, San Francisco
  • 1995 - 2002
    Associate Adjunct Professor, Department of Radiology, University of California, San Francisco 
  • 2002 - present
    Professor in Residence, Department of Radiology, University of California, San Francisco

 

Honors & Awards

  • 2010
    Komen Scholar, Komen for the Cure
  • 2013
    Distinguished Lectureship Award, Sigma Xi
  • 2013
    Distinguished Investigator Award, Academy of Radiology Research
  • 2017
    Fellow, International Society of Magnetic Resonance in Medicine

Selected Publications

  1. Jahani N, Cohen E, Hsieh MK, Weinstein SP, Pantalone L, Hylton N, Newitt D, Davatzikos C, Kontos D. Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. Sci Rep. 2019 Aug 20; 9(1):12114.
    View on PubMed
  2. Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, Esserman LJ, Hylton NM. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL. J Magn Reson Imaging. 2019 Apr 26.
    View on PubMed
  3. Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer. 2019; 5:12.
    View on PubMed
  4. Partridge SC, Newitt DC, Chenevert TL, Rosen MA, Hylton NM. Diffusion-weighted MRI in Multicenter Trials of Breast Cancer. Radiology. 2019 May; 291(2):546.
    View on PubMed
  5. Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. J Magn Reson Imaging. 2018 Oct 22.
    View on PubMed
  6. Cochran JM, Busch DR, Leproux A, Zhang Z, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue B, Jiang S, Kaufman PA, Chung SH, Schnall M, Snyder BS, Hylton N, Carp SA, Isakoff SJ, Mankoff D, Tromberg BJ, Yodh AG. Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. J Biomed Opt. 2018 Oct; 24(2):1-11.
    View on PubMed
  7. Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology. 2018 Dec; 289(3):618-627.
    View on PubMed
  8. Hylton NM. Residual Disease after Neoadjuvant Therapy for Breast Cancer: Can MRI Help? Radiology. 2018 Nov; 289(2):335-336.
    View on PubMed
  9. Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y. Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis. NPJ Breast Cancer. 2018; 4:24.
    View on PubMed
  10. Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM. The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. Int J Radiat Oncol Biol Phys. 2018 Nov 15; 102(4):1219-1235.
    View on PubMed
  11. Jung S, Goloubeva O, Hylton N, Klifa C, LeBlanc E, Shepherd J, Snetselaar L, Van Horn L, Dorgan JF. Intake of dietary carbohydrates in early adulthood and adolescence and breast density among young women. Cancer Causes Control. 2018 Jul; 29(7):631-642.
    View on PubMed
  12. Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018 Jun; 210(6):1376-1385.
    View on PubMed
  13. Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham). 2018 01; 5(1):011014.
    View on PubMed
  14. Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN. Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices. Radiology. 2018 03; 286(3):822-829.
    View on PubMed
  15. Newitt DC, Malyarenko D, Chenevert TL, Quarles CC, Bell L, Fedorov A, Fennessy F, Jacobs MA, Solaiyappan M, Hectors S, Taouli B, Muzi M, Kinahan PE, Schmainda KM, Prah MA, Taber EN, Kroenke C, Huang W, Arlinghaus LR, Yankeelov TE, Cao Y, Aryal M, Yen YF, Kalpathy-Cramer J, Shukla-Dave A, Fung M, Liang J, Boss M, Hylton N. Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. J Med Imaging (Bellingham). 2018 Jan; 5(1):011003.
    View on PubMed
  16. Bane O, Hectors SJ, Wagner M, Arlinghaus LL, Aryal MP, Cao Y, Chenevert TL, Fennessy F, Huang W, Hylton NM, Kalpathy-Cramer J, Keenan KE, Malyarenko DI, Mulkern RV, Newitt DC, Russek SE, Stupic KF, Tudorica A, Wilmes LJ, Yankeelov TE, Yen YF, Boss MA, Taouli B. Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study. Magn Reson Med. 2018 05; 79(5):2564-2575.
    View on PubMed
  17. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017; 3:31.
    View on PubMed
  18. O'Sullivan TD, Cerussi A, Durkin A, Hill B, Hylton N, Yodh AG, Carp SA, Boas D, Jiang S, Paulsen KD, Pogue B, Roblyer D, Yang W, Tromberg BJ. Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial J Biomed Opt. 2017 12 01; 22(12):121604.
    View on PubMed
  19. Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 06; 17(3):e155-e159.
    View on PubMed
  20. Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging. 2017 07; 46(1):290-302.
    View on PubMed

Go to UCSF Profiles, powered by CTSI